ASCO 2024: Latest Data in Melanoma : Episode 5
Opinion
Video
Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma
Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson.
Video content above is prompted by the following:
- Discuss the 3-year updated data presented at ASCO 2024 on individualized neoantigen therapy (mRNA-4157) plus pembrolizumab in resected melanoma.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Please provide your key takeaways from this study. How might these findings impact the management of patients with melanoma?
Related Videos
Related Content
